Smith & Nephew SNATS (NYSE:SNN) Downgraded by Wall Street Zen to “Buy”

Smith & Nephew SNATS (NYSE:SNN) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday.

Several other analysts have also weighed in on the stock. Sanford C. Bernstein set a $37.50 price objective on shares of Smith & Nephew SNATS and gave the stock a “market perform” rating in a report on Tuesday, October 14th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Kepler Capital Markets raised Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Finally, Canaccord Genuity Group decreased their target price on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Smith & Nephew SNATS has a consensus rating of “Hold” and an average price target of $35.75.

Smith & Nephew SNATS Stock Up 0.3%

Shares of SNN stock opened at $32.81 on Monday. Smith & Nephew SNATS has a 12-month low of $23.69 and a 12-month high of $38.79. The firm has a 50-day moving average price of $34.11 and a 200 day moving average price of $33.83. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40.

Institutional Investors Weigh In On Smith & Nephew SNATS

A number of institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Smith & Nephew SNATS by 11.7% in the third quarter. GAMMA Investing LLC now owns 3,837 shares of the medical equipment provider’s stock valued at $139,000 after acquiring an additional 401 shares during the last quarter. Versant Capital Management Inc raised its holdings in Smith & Nephew SNATS by 5.0% during the 3rd quarter. Versant Capital Management Inc now owns 8,912 shares of the medical equipment provider’s stock worth $323,000 after purchasing an additional 423 shares during the last quarter. Vise Technologies Inc. lifted its position in Smith & Nephew SNATS by 4.7% during the 3rd quarter. Vise Technologies Inc. now owns 9,642 shares of the medical equipment provider’s stock valued at $350,000 after purchasing an additional 437 shares during the period. Quadrant Capital Group LLC lifted its position in Smith & Nephew SNATS by 3.6% during the 3rd quarter. Quadrant Capital Group LLC now owns 12,757 shares of the medical equipment provider’s stock valued at $463,000 after purchasing an additional 440 shares during the period. Finally, First Trust Advisors LP boosted its stake in shares of Smith & Nephew SNATS by 4.6% in the 3rd quarter. First Trust Advisors LP now owns 10,532 shares of the medical equipment provider’s stock valued at $382,000 after purchasing an additional 459 shares during the last quarter. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.